Malik Fady Ibraham 4

What Happened
Malik Fady Ibraham, Executive Vice President, Research & Development at Cytokinetics (CYTK), sold 2,907 shares on 2026-03-09 at $60.72 per share, generating $176,513. The Form 4 was filed on 2026-03-10. This was a sale (S) and not a purchase; such sales are often routine rather than a direct signal about company prospects.

Key Details

• Transaction date and price: 2026-03-09 at $60.72 per share; total proceeds ~$176,513.
• Shares owned after transaction: Not disclosed in this filing.
• Footnote: F1 indicates this was a "sell to cover" to satisfy company tax withholding obligations upon vesting of RSUs.
• Filing timeliness: Report filed 2026-03-10 for a 2026-03-09 transaction — appears timely (no late filing indicated).

Context
A "sell-to-cover" is a common automatic transaction when restricted stock units vest and taxes are withheld; it does not necessarily reflect the insider’s view of the company. For retail investors, purchases typically carry more informational weight than routine sell-to-cover transactions.